Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma

NCT03579771 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03579771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03579771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Feasibility Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk Intrahepatic Cholangiocarcinoma
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Completed
Start date
September 26, 2018
Completion date
September 16, 2023
Enrollment
30 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

resectable cholangiocarcinoma, stage ib intrahepatic cholangiocarcinoma ajcc v8, stage ii intrahepatic cholangiocarcinoma ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iiia intrahepatic cholangiocarcinoma ajcc v8, stage iiib intrahepatic cholangiocarcinoma ajcc v8